Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × erdafitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 6 Non-Muscle Invasive Bladder Neoplasms 5 Multiple Myeloma 3 Glioma 3 Carcinoma, Transitional Cell 3 Wilms Tumor 2 Urothelial Cancer 2 Rhabdoid Tumor 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasms 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Acrocephalosyndactylia 2 Xanthogranuloma, Juvenile 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rare Tumour 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1

Interventions

Carboplatin 274 Paclitaxel 273 Bevacizumab 148 liposomal doxorubicin 86 pembrolizumab 84 Gemcitabine 82 Cyclophosphamide 81 olaparib 79 Cisplatin 75 Topotecan 72 niraparib 59 Docetaxel 49 Doxorubicin 44 Drug Therapy 38 fludarabine 35 Taxes 35 Nivolumab 32 Filgrastim 31 Specimen Handling 29 Etoposide 28 Surveys and Questionnaires 27 Magnetic Resonance Spectroscopy 27 Hyperthermic Intraperitoneal Chemotherapy 27 Peripheral Blood Stem Cell Transplantation 23 durvalumab 21 Immunoglobulin G 21 Disulfides 21 Cytoreduction Surgical Procedures 21 Blood Specimen Collection 21 Biopsy 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06328491 2024-03-25

Erdafitinib in Metastatic Steroid-cell Ovarian Cancer

University Health Network, Toronto

Phase NA Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡